Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burns | 15 | 2023 | 113 | 9.720 |
Why?
|
| Surgery, Plastic | 2 | 2020 | 46 | 1.470 |
Why?
|
| Surgeons | 2 | 2020 | 192 | 1.160 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2023 | 23 | 0.970 |
Why?
|
| Antifibrinolytic Agents | 1 | 2023 | 27 | 0.950 |
Why?
|
| Mediastinal Emphysema | 1 | 2022 | 6 | 0.940 |
Why?
|
| Hemostatics | 1 | 2023 | 54 | 0.940 |
Why?
|
| Facial Nerve Injuries | 1 | 2022 | 10 | 0.940 |
Why?
|
| Blast Injuries | 1 | 2022 | 10 | 0.930 |
Why?
|
| Facial Injuries | 1 | 2022 | 18 | 0.930 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 85 | 0.920 |
Why?
|
| Shock, Septic | 1 | 2023 | 83 | 0.920 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2021 | 21 | 0.890 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2021 | 29 | 0.890 |
Why?
|
| Compartment Syndromes | 1 | 2021 | 12 | 0.850 |
Why?
|
| Intraocular Pressure | 1 | 2021 | 51 | 0.840 |
Why?
|
| Orbital Diseases | 1 | 2021 | 21 | 0.830 |
Why?
|
| Bone Nails | 1 | 2020 | 17 | 0.810 |
Why?
|
| Homeless Persons | 1 | 2020 | 25 | 0.800 |
Why?
|
| Critical Care | 1 | 2021 | 350 | 0.700 |
Why?
|
| Mastectomy, Segmental | 1 | 2018 | 89 | 0.640 |
Why?
|
| Family Practice | 1 | 2017 | 80 | 0.630 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 135 | 0.630 |
Why?
|
| Burn Units | 3 | 2022 | 19 | 0.620 |
Why?
|
| Mammaplasty | 1 | 2018 | 100 | 0.600 |
Why?
|
| Emergency Medicine | 1 | 2017 | 117 | 0.580 |
Why?
|
| Referral and Consultation | 1 | 2018 | 307 | 0.550 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 426 | 0.530 |
Why?
|
| Primary Health Care | 1 | 2017 | 318 | 0.500 |
Why?
|
| Cleft Lip | 1 | 2013 | 15 | 0.500 |
Why?
|
| Cleft Palate | 1 | 2013 | 25 | 0.490 |
Why?
|
| Indians, North American | 1 | 2013 | 48 | 0.490 |
Why?
|
| Canada | 3 | 2020 | 195 | 0.480 |
Why?
|
| Blood Loss, Surgical | 2 | 2023 | 108 | 0.450 |
Why?
|
| Humans | 20 | 2023 | 81308 | 0.450 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 2310 | 0.430 |
Why?
|
| Clinical Competence | 1 | 2017 | 722 | 0.430 |
Why?
|
| Internship and Residency | 1 | 2020 | 928 | 0.430 |
Why?
|
| Retrospective Studies | 7 | 2022 | 7600 | 0.390 |
Why?
|
| Length of Stay | 3 | 2022 | 658 | 0.380 |
Why?
|
| Adult | 8 | 2022 | 24771 | 0.320 |
Why?
|
| Hospitalization | 2 | 2020 | 770 | 0.250 |
Why?
|
| Administration, Topical | 1 | 2023 | 92 | 0.240 |
Why?
|
| Bandages | 1 | 2023 | 37 | 0.240 |
Why?
|
| Adolescent | 3 | 2022 | 8736 | 0.240 |
Why?
|
| Vasoconstrictor Agents | 1 | 2023 | 51 | 0.240 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1419 | 0.230 |
Why?
|
| Cheek | 1 | 2022 | 20 | 0.230 |
Why?
|
| Female | 7 | 2022 | 42685 | 0.230 |
Why?
|
| Epinephrine | 1 | 2022 | 86 | 0.230 |
Why?
|
| Hair | 1 | 2022 | 54 | 0.230 |
Why?
|
| Frailty | 1 | 2022 | 31 | 0.220 |
Why?
|
| Body Surface Area | 1 | 2021 | 35 | 0.220 |
Why?
|
| Research Report | 1 | 2022 | 45 | 0.220 |
Why?
|
| Child | 2 | 2023 | 6639 | 0.210 |
Why?
|
| Skin Transplantation | 1 | 2022 | 172 | 0.210 |
Why?
|
| Physical Abuse | 1 | 2020 | 4 | 0.210 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 133 | 0.210 |
Why?
|
| Los Angeles | 1 | 2020 | 27 | 0.210 |
Why?
|
| Male | 5 | 2023 | 39770 | 0.200 |
Why?
|
| Water | 1 | 2022 | 263 | 0.200 |
Why?
|
| Resuscitation | 1 | 2021 | 93 | 0.200 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 89 | 0.200 |
Why?
|
| Hypoglycemia | 1 | 2021 | 102 | 0.200 |
Why?
|
| Enteral Nutrition | 1 | 2020 | 98 | 0.200 |
Why?
|
| Patient Positioning | 1 | 2020 | 57 | 0.190 |
Why?
|
| Intraoperative Care | 1 | 2020 | 82 | 0.190 |
Why?
|
| Motivation | 1 | 2022 | 272 | 0.180 |
Why?
|
| Wound Healing | 1 | 2021 | 338 | 0.180 |
Why?
|
| United States | 2 | 2022 | 6191 | 0.180 |
Why?
|
| Operating Rooms | 1 | 2020 | 119 | 0.180 |
Why?
|
| Self-Injurious Behavior | 1 | 2020 | 102 | 0.170 |
Why?
|
| Esthetics | 1 | 2018 | 50 | 0.170 |
Why?
|
| Critical Illness | 1 | 2020 | 265 | 0.170 |
Why?
|
| Personnel Selection | 1 | 2018 | 52 | 0.160 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 78 | 0.160 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2018 | 110 | 0.160 |
Why?
|
| Young Adult | 2 | 2020 | 5754 | 0.160 |
Why?
|
| Mental Disorders | 1 | 2020 | 362 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 345 | 0.150 |
Why?
|
| Self Report | 1 | 2018 | 271 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 154 | 0.150 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1698 | 0.150 |
Why?
|
| Child, Preschool | 1 | 2023 | 3569 | 0.150 |
Why?
|
| General Surgery | 1 | 2018 | 215 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2595 | 0.140 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 3586 | 0.130 |
Why?
|
| Aged | 4 | 2022 | 17570 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2020 | 2600 | 0.130 |
Why?
|
| Treatment Refusal | 1 | 2012 | 55 | 0.110 |
Why?
|
| Complementary Therapies | 1 | 2012 | 50 | 0.110 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 2756 | 0.110 |
Why?
|
| Women's Health | 1 | 2012 | 93 | 0.110 |
Why?
|
| Middle Aged | 3 | 2018 | 24127 | 0.100 |
Why?
|
| Rhombencephalon | 1 | 2009 | 49 | 0.090 |
Why?
|
| Registries | 1 | 2013 | 655 | 0.090 |
Why?
|
| Respiratory Center | 1 | 2009 | 53 | 0.090 |
Why?
|
| Prevalence | 1 | 2013 | 1190 | 0.090 |
Why?
|
| Adenosine Triphosphate | 1 | 2009 | 305 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2013 | 2291 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6244 | 0.080 |
Why?
|
| Prognosis | 2 | 2022 | 3549 | 0.050 |
Why?
|
| Energy Intake | 1 | 2020 | 95 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2022 | 323 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 329 | 0.050 |
Why?
|
| Inpatients | 1 | 2022 | 276 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 363 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 347 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2012 | 224 | 0.030 |
Why?
|
| Adenosine A1 Receptor Agonists | 1 | 2009 | 1 | 0.020 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2009 | 4 | 0.020 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 14 | 0.020 |
Why?
|
| 5'-Nucleotidase | 1 | 2009 | 13 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2009 | 53 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2009 | 132 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 430 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2009 | 89 | 0.020 |
Why?
|
| Periodicity | 1 | 2009 | 123 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2009 | 102 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2009 | 523 | 0.020 |
Why?
|
| Respiration | 1 | 2009 | 249 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1548 | 0.020 |
Why?
|
| Adenosine | 1 | 2009 | 218 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1200 | 0.020 |
Why?
|
| Action Potentials | 1 | 2009 | 585 | 0.020 |
Why?
|
| Rats | 1 | 2009 | 3944 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2012 | 7589 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 25878 | 0.010 |
Why?
|